

Orange Biomed was selected by Fortune Korea as one of the "Top 40 Promising Healthcare Innovators for the US Market."

We expect to accelerate our entry into the North American market by leveraging our global network.

Reporter Lee Kwon | -gu kwon9@yakup.com Posted 2025.08.18 08:32 Modified 2025.08.18 10:07

ORANGE BIOMED

Orange Biomed (CEO Woong-Hyeon Koh and Yeseul Park), a medical device for measuring glycated hemoglobin (A1C) based on microfluidics, announced on the 18th that it was selected as one of the '40 Korean Healthcare Innovation Companies' (Fortune Korea's Top 40 'Emerging S. Korean Healthcare Innovations') by the global economic magazine Fortune Korea.

This selection was based on an evaluation by leading US healthcare authorities (Key Opinion Leaders (KOLs)) and industry experts, along with the US-based global consulting firm BDMT Global. Innovative companies in the AI, digital health, and MedTech sectors were selected through a comprehensive evaluation of their feasibility, innovation, and market fit for the US healthcare market. Companies with technologies that can address unmet needs in the US healthcare sector received particularly high scores.

The evaluation panel stated, “Many patients are unable to properly monitor their diabetes due to barriers to laboratory testing,” and “Orange Biomed’s microfluidic technology-based compact OBM rapid A1c has the potential to revolutionize the accessibility of diabetes monitoring.”

Orange Biomed possesses a physical glycated hemoglobin measurement technology based on microfluidic technology. Furthermore, it is promoting the "MAP YOUR HEALTH" campaign to

prevent chronic diseases. On the 16th, it successfully held the "MAP YOUR HEALTH Chicago" event in Chicago, USA, in partnership with over 18 health and community organizations.

Orange Biomed CEO Park Ye-seul said, “Being selected as Fortune Korea Top 40 is a meaningful stepping stone for Orange Biomed to establish itself as a leading player in global healthcare innovation,” and added, “We will expand our participation in major healthcare events and networking opportunities in North America and lead to tangible business results in the U.S. healthcare market.”

Orange Biomed is a bio-healthcare company developing a portable glycated hemoglobin (A1C) measuring medical device based on microfluidic technology. It has achieved a cumulative investment of KRW 10.1 billion by 2025 and has received the KHF Innovation Award in recognition of its technological innovation.

We are accelerating the expansion of our base for entering the global market by showcasing our innovative technologies at domestic and international academic conferences such as the American Diabetes Association (ADA), the Diabetes Technology Society (DTM), the Korean Diabetes Association, the American College of Diagnostic and Laboratory Medicine (ADLM), and the American Society for Diabetes Care and Education (ADCES), as well as at international exhibitions such as MEDICA in Germany and CES in the United States.

We are continuing our preparations with the goal of obtaining US FDA approval in 2026, and plan to further expand accessibility to innovative diabetes management solutions through future commercialization.

cancellation

Print

Copyright © Yakup.com All rights reserved.

All content (articles) in the Pharmaceutical Newspaper are protected by copyright law.
Unauthorized reproduction, copying, or distribution is prohibited.